Zobrazeno 1 - 3
of 3
pro vyhledávání: '"intolerance/toxicity"'
Autor:
L. Testa, Sara Melzi, Elisabetta Chiesa, Teresa Bini, Fulvio Adorni, B. Castelnuovo, Salvatore Sollima, A d'Arminio Monforte, C. Abeli, Marco Bongiovanni
Publikováno v:
Journal of acquired immune deficiency syndromes (1999) 24 (2000): 115–122.
info:cnr-pdr/source/autori:Bini, T; Testa, L; Chiesa, E; Adorni, F; Abeli, C; Castelnuovo, B; Melzi, S; Sollima, S; Bongiovanni, M; Monforte, AD/titolo:Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy/doi:/rivista:Journal of acquired immune deficiency syndromes (1999)/anno:2000/pagina_da:115/pagina_a:122/intervallo_pagine:115–122/volume:24
info:cnr-pdr/source/autori:Bini, T; Testa, L; Chiesa, E; Adorni, F; Abeli, C; Castelnuovo, B; Melzi, S; Sollima, S; Bongiovanni, M; Monforte, AD/titolo:Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy/doi:/rivista:Journal of acquired immune deficiency syndromes (1999)/anno:2000/pagina_da:115/pagina_a:122/intervallo_pagine:115–122/volume:24
The outcome of second-line protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) was investigated in 263 patients who were failed by (n = 148) or intolerant of (n = 115) a first HAART regimen. The endpoints were virologic fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d89632128bd881fbd09f47d1a9eef67
https://doi.org/10.1097/00042560-200006010-00005
https://doi.org/10.1097/00042560-200006010-00005
Autor:
Bini, T., Testa, L., Chiesa, E., Fulvio Adorni, Abeli, C., Castelnuovo, B., Melzi, S., Sollima, S., Bongiovanni, M., D Arminio Monforte, A.
Publikováno v:
Journal of acquired immune deficiency syndromes (1999) 24 (2000): 115–122.
info:cnr-pdr/source/autori:Bini T.; Testa L.; Chiesa E.; Adorni F.; Abeli C.; Castelnuovo B.; Melzi S.; Sollima S.; Bongiovanni M.; D'Arminio Monforte A./titolo:Outcome of a second-line protease inhibitor-Containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy/doi:/rivista:Journal of acquired immune deficiency syndromes (1999)/anno:2000/pagina_da:115/pagina_a:122/intervallo_pagine:115–122/volume:24
Scopus-Elsevier
info:cnr-pdr/source/autori:Bini T.; Testa L.; Chiesa E.; Adorni F.; Abeli C.; Castelnuovo B.; Melzi S.; Sollima S.; Bongiovanni M.; D'Arminio Monforte A./titolo:Outcome of a second-line protease inhibitor-Containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy/doi:/rivista:Journal of acquired immune deficiency syndromes (1999)/anno:2000/pagina_da:115/pagina_a:122/intervallo_pagine:115–122/volume:24
Scopus-Elsevier
The outcome of second-line protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART) was investigated in 263 patients who were failed by (n 148) or intolerant of (n 115) a first HAART regimen. The endpoints were virologic failur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e3d3858750cda00aa2c88ceb6575bdaa
https://publications.cnr.it/doc/353268
https://publications.cnr.it/doc/353268
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.